Takeda

NEWS DESK

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

PR News Desk 06/09/2025

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the

NEWS DESK

Takeda appoints Hernán Porcile as Head of the EAMEA region, continuing its legacy of visionary leadership

PR News Desk 23/07/2025

Takeda, a global, research and development-driven biopharmaceutical leader, has appointed Hernán Porcile as the new Area Head for its Eurasia[1], Middle East and Africa (EAMEA) region. Formerly General Manager of Takeda Mexico, Hernán Porcile assumed his new role on July 1, 2025, and is now based in Dubai, United Arab Emirates, from where he will […]

NEWS DESK

Takeda successfully hosted the IBD Nexus Summit 2025 in the UAE

PR News Desk 03/02/2025

Takeda, a global biopharmaceutical leader focused on patient care and one of the key players in the Inflammatory Bowel Disease (IBD) space, hosted the IBD Nexus Summit 2025 at Sofitel Dubai the Obelisk. This two-day event aimed to advance IBD patient care by raising awareness, enhancing understanding of the disease, and sharing diverse insights, all […]

NEWS DESK

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

PR News Desk 30/01/2025

Takeda (TOKYO:4502/NYSE:TAK) announced today that itsBoard of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be

NEWS DESK

Takeda Delivers Strong Third-Quarter FY2024 Results

PR News Desk 30/01/2025

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product

NEWS DESK

Takeda Announces Approval of HYQVIA® 10% S.C.

PR News Desk 27/12/2024

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk

NEWS DESK

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments

PR News Desk 13/12/2024

Takeda (TSE:4502/NYSE:TAK) willhost an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage

NEWS DESK

Takeda Receives Prestigious Recognitions: The Best Workplace Certificate GCC 2024

News Desk 17/10/2024

Takeda Gulf Cooperation Council (GCC) has been honored with the “Best Workplace GCC 2024” and the “Best Workplace for Women GCC 2024” certifications. These prestigious accolades are a testament to Takeda’s ongoing commitment to fostering a positive, inclusive, and supportive workplace culture. The “Best Workplace” award recognizes organizations that excel in creating an

NEWS DESK

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan

PR News Desk 25/09/2024

Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC)

NEWS DESK

Takeda to Present Additional Clinical Trial Study Data

PR News Desk 19/09/2024

Takeda(TSE:4502/NYSE:TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in Seville, Spain.

NEWS DESK

Takeda Receives European Commission Approval for ADZYNMA

PR News Desk 07/08/2024

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP).3 ADZYNMA is now the first and only enzyme replacement therapy in the European Union (EU) specifically for the

NEWS DESK

Takeda Announces New Assignments of Directors

News Desk 26/06/2024

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda’s Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure

NEWS DESK

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan

News Desk 24/06/2024

Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and

NEWS DESK

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab

News Desk 24/06/2024

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction

NEWS DESK

Takeda Receives Approval from European Commission

News Desk 22/06/2024

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF

NEWS DESK

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA

News Desk 18/06/2024

Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Results showed favorable long-term

NEWS DESK

Takeda Announces Phase 3 Topline Results for Soticlestat

News Desk 18/06/2024

Takeda (TSE:4502/NYSE:TAK) today announced topline data from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat (TAK-935) plus standard of care versus placebo plus standard of care in patients with refractory Dravet syndrome (DS).1 Soticlestat narrowly missed the primary endpoint

NEWS DESK

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib

News Desk 14/06/2024

Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised,

NEWS DESK

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations

News Desk 03/06/2024

Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin receptor 2 (OX2R) agonist and, based on […]

NEWS DESK

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS

News Desk 03/06/2024

Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting